These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 17451183

  • 21. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.
    Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonça A.
    Prog Neurobiol; 2007 Dec; 83(5):310-31. PubMed ID: 18023959
    [Abstract] [Full Text] [Related]

  • 22. MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases.
    Mason GF, Krystal JH.
    NMR Biomed; 2006 Oct; 19(6):690-701. PubMed ID: 16986118
    [Abstract] [Full Text] [Related]

  • 23. Enriched environments, experience-dependent plasticity and disorders of the nervous system.
    Nithianantharajah J, Hannan AJ.
    Nat Rev Neurosci; 2006 Sep; 7(9):697-709. PubMed ID: 16924259
    [Abstract] [Full Text] [Related]

  • 24. The brain as a target for inflammatory processes and neuroprotective strategies.
    Skaper SD.
    Ann N Y Acad Sci; 2007 Dec; 1122():23-34. PubMed ID: 18077562
    [Abstract] [Full Text] [Related]

  • 25. [Therapeutic strategies and Alzheimer's disease: contribution of animal models].
    Chabrier PE.
    Ann Pharm Fr; 2009 Mar; 67(2):97-103. PubMed ID: 19298893
    [Abstract] [Full Text] [Related]

  • 26. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease.
    Henchcliffe C, Shungu DC, Mao X, Huang C, Nirenberg MJ, Jenkins BG, Beal MF.
    Ann N Y Acad Sci; 2008 Dec; 1147():206-20. PubMed ID: 19076443
    [Abstract] [Full Text] [Related]

  • 27. Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases.
    Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D.
    Isr Med Assoc J; 2009 Apr; 11(4):201-4. PubMed ID: 19603590
    [Abstract] [Full Text] [Related]

  • 28. Nortriptyline delays disease onset in models of chronic neurodegeneration.
    Wang H, Guan Y, Wang X, Smith K, Cormier K, Zhu S, Stavrovskaya IG, Huo C, Ferrante RJ, Kristal BS, Friedlander RM.
    Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
    [Abstract] [Full Text] [Related]

  • 29. Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases.
    Janus C.
    Genes Brain Behav; 2008 Feb; 7 Suppl 1():12-27. PubMed ID: 18184367
    [Abstract] [Full Text] [Related]

  • 30. Magnetic resonance of mouse models of cardiac disease.
    Hiller KH, Waller C, Haase A, Jakob PM.
    Handb Exp Pharmacol; 2008 Feb; (185 Pt 2):245-57. PubMed ID: 18626605
    [Abstract] [Full Text] [Related]

  • 31. Changes in adult neurogenesis in neurodegenerative diseases: cause or consequence?
    Thompson A, Boekhoorn K, Van Dam AM, Lucassen PJ.
    Genes Brain Behav; 2008 Feb; 7 Suppl 1():28-42. PubMed ID: 18184368
    [Abstract] [Full Text] [Related]

  • 32. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM, Rego AC.
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [Abstract] [Full Text] [Related]

  • 33. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern.
    Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, Schulz-Schaeffer W, Fassbender K.
    Neurobiol Aging; 2009 May; 30(5):759-68. PubMed ID: 17905482
    [Abstract] [Full Text] [Related]

  • 34. Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment.
    Griffith HR, Stewart CC, den Hollander JA.
    Int Rev Neurobiol; 2009 May; 84():105-31. PubMed ID: 19501715
    [Abstract] [Full Text] [Related]

  • 35. Effects of enriched environment on animal models of neurodegenerative diseases and psychiatric disorders.
    Laviola G, Hannan AJ, Macrì S, Solinas M, Jaber M.
    Neurobiol Dis; 2008 Aug; 31(2):159-68. PubMed ID: 18585920
    [Abstract] [Full Text] [Related]

  • 36. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM, Amiji MM.
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [Abstract] [Full Text] [Related]

  • 37. PPAR: a therapeutic target in Parkinson's disease.
    Chaturvedi RK, Beal MF.
    J Neurochem; 2008 Jul; 106(2):506-18. PubMed ID: 18384649
    [Abstract] [Full Text] [Related]

  • 38. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K, Robotka H, Toldi J, Vécsei L.
    J Neurol Sci; 2007 Jun 15; 257(1-2):221-39. PubMed ID: 17462670
    [Abstract] [Full Text] [Related]

  • 39. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ.
    Med Hypotheses; 2007 Jun 15; 69(6):1219-21. PubMed ID: 17548170
    [Abstract] [Full Text] [Related]

  • 40. Environmental enrichment and neurodegenerative diseases.
    Li L, Tang BL.
    Biochem Biophys Res Commun; 2005 Aug 26; 334(2):293-7. PubMed ID: 15961061
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.